Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial

Clinical Cancer Research · Published 2026-07-23 · DOI 10.1158/1078-0432.ccr-26-1456

Free full text

Authors (14)

Zev A. Wainberg, Keun-Wook Lee, Jong Gwang Kim, Craig Devoe, John H. Strickler, Jason Baum, Calvin Jia, Michael H. Kagey, Cynthia A. Sirard, Alexander Stein, Aaron James Scott, Meredith Pelster, Markus Moehler, Sae-Won Han

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wainberg, Z., Lee, K., Kim, J., et al. (2026). Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-1456

Related articles

• Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial · Clinical Cancer Research · 2026 · Same journal
• First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma · Clinical Cancer Research · 2026 · Same journal
• Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma · Clinical Cancer Research · 2026 · Same journal
• Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT) · Clinical Cancer Research · 2026 · Same journal
• Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study · Clinical Cancer Research · 2026 · Same journal
• Preclinical characterization of CLSP-1025, a first-in-class, mutation-specific T-cell engager targeting a neoantigen derived from a common p53 mutation · Clinical Cancer Research · 2026 · Same journal
• Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial · Clinical Cancer Research · 2026 · Same journal
• FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal · Clinical Cancer Research · 2026 · Same journal
• Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight loss (A-NEW) Study · Clinical Cancer Research · 2026 · Same journal
• A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02 · Clinical Cancer Research · 2026 · Same journal